FREDUN PHARMACEUTICALS LIMITED

compassionate healthcare



FREDUN PHARMACEUTICALS LTD.

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THREE MONTHS ENDED 30-Jun-12

NO	DARTICULA DO	T			Rs. in Lacs
NO	PARTICULARS	Quarter ended			Year ended
		30.06.2012	31.03.2012	30.06.2011	31.03.2012
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
-	Net Sales /IncomeFrom Operation (Net of				
1	Excise Duty)	395.23	322.66	202.58	1167.54
	Other Income	3.84	7.71	3.06	27.27
3	Total Expenditure	362.00	292.37	175.23	1055.93
	Increase/Decrease in stock in trade	93.52	(117.02)		(192.54)
b	Consumption of raw materials	127.18	138.51	119.10	600.12
	Staff cost	42.82	49.25	33,45	163.53
đ	Other Expenditure	98.48	221.63	75.05	484.82
	(Any item exceeding 10% of the total				
	expenditure to be shown separately				
	Profit before interest, depreciation			į	
	and tax	37.07	38.00	30.41	138.88
. 1	Interest	22.34	32.41	16.77	89.72
	Depreciation	11.08	5.21	10.12	35.44
	Profit (+)/Loss(-) before tax				
	(1+2-3-4-5)	3.65	0.38	3.52	13.72
	Provision for taxation				
	Current Tax	0.80	(2.48)	0.90	0.62
	Deferred Tax	0.00	0.56	0.00	0.56
	Net Profit (+)/Loss(-)				0.50
	(7-8)	2.85	2.30	2.62	12.54
	Paid up Equity Share Capital	237.45	237.45	237.45	237,45
-11	Reserves excluding Revaluation Reserves				
	(as per Balance Sheet of previous account-				
	-ing years). To be given in column (3)				
12	Basic and Diluted EPS for the period for the				
	year (not to be annualised)	0.12	0.10	0.11	0.53
. 13	Aggregate of Non-promoting Shareholding			-	
	Number of shares	440300	440300	440300	440300
NOTES	Percentage of shareholding	18.72	18.72	18.72	18.72

- 1) The above results were taken on record by the Board Of Directors at the meeting held on 14.08.2012.
- 2) The Statutory Auditors of the Company have carried out a Limited Review of the above unaudited financial results.
- 3) Previous year's figures have been regrouped/rearranged wherever necessary.
- 4) During the quarter ended 30th June 2012 there are no investor's complaints pending & no investor's complaints were received by the company during this period.
- 5) Provision for deferred tax as per Accounting Standard 22 of the institute of Chartered Accountants of India as applicable will be made at the end of the year.
- 6) Dividend on Preference shares will be considered at the year end.
- 7) Figures for quarter and year ending 31.03.2012 have been rectified. Previous sales figures rectified as net of excise duty.

PLACE: MUMBAI

DATE: 14.08.2012

FOR FREDUN PHARMACEUTICALS LIMITED

tomedha

JOINT MANAGING DIRECTOR.

Office: 26, Manoj Industrial Premises,

G. D. Ambekar Marg, Wadala, Mumbai - 400 031. INDIA.

Phone: 91-22-40318111 Fax: 91-22-40318133

E-mail: info@fredunpharma.com Web: www.fredunpharma.com

Factory: 14,15,16, Zorabain Industrial Complex,

Veoor, Palghar (E). Dist -Thane - 401 404, INDIA. Phone: 02525-253194 Fax: 02525-253193